Samenvatting
Summary Molecular Therapy
- Instelling
- Radboud Universiteit Nijmegen (RU)
Summary molecular therapy lectures.
[Meer zien]Voorbeeld 4 van de 77 pagina's
Voorbeeld 4 van de 77 pagina's
In winkelwagengesponsord bericht van onze partner
Verkoper
Volgen
Voorbeeld van de inhoud
Molecular TherapyPharmacodynamics and -kinetics
Lecture: Personalized healthcare
Principle of personalized healthcare
- The right therapy for the right patients at right intensity at right time
- Molecular biomarkes as key drivers of patients selection
- = personalized medicine, precision medicine
- Personalized healthcare: Drug not toxic and beneficial
Example: melanoma
BRAF mutation
- Protein: part of the ERK pathway (growth pathway)
o ERK pathway: all kinases, 2 phosphorylation sites who both need to be
phosphorylated to initiate kinase cascade
If there is a mutation, these cell will grow uncontrolled, and become cancer cells
- Drug development: inhibition of this pathway = kinase inhibitor, thus B-RAF inhibitor (nib at
end of drug means kinase inhibitor)
60% of melanoma patients have a BRAF mutation, so this is a good basis for personalized medicine!
- ZELBORAF (vemurafenib) is a successful B-RAF inhibitor used in clinical practice for
melanoma
o However; problem occurred → drug resistance
o Combination: drug + chemo
Biomarkers:
- Characteristic that is objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic
intervention
o molecular biomarkers provide a molecular impression of a biological system
o biomarkers can be carious sorts of data, of combinations thereof
biomarker data can be used to make driver decisions during drug discovery and development
- 5R’s assessment
o Right target
o Right tissue
o Right safety
o Right patients
o Right commercial potential
Leading to an increase of R&D productivity
Drug discovery and development phases
1. Research
2. Lead finding (high throughput screening, is a drug good for clinical)
3. Preclinical (toxicity and bioavailability)
4. Phase 1 (low dose)
5. Phase 2 (right dose)
, 6. Phase 3 (more people, 1 dose)
Personalized healthcare
- In rare metabolic diseases
Story: normal Dutch parents, 2 children (boys), both died (age 3.5, 1.5)
Symptoms: low birth weight, lactic acidosis, hypoglycaemia, intellectual disability, movement
disorder, epilepsy
What did they see after lab tests:
1. Biomarkers for mitochondrial disease where low: ATP production and creatine phosphate
production
2. But no diversions in the OXPHOS enzyme complexes
3. No variant found in candidate sequencing
But, after whole exome sequencing: mutation on WARS2 was found
- WARS2 is mtDN-coded tryptophanyl-tRNA synstase
- Mutation caused instability of the WARS2 protein leading to less charging of Trp-tRNA =
mitochondrial encephalopathy
A new prenatal genetic test was developed to screen for this mutation in unborn children
- Disease was maternal inherited and X-linked
= example of personalized healthcare
Lessons learned:
1. Technology innovation is driving impact I personalized healthcare
2. Crucial to combine different molecular views to understand human health and disease (X-
omics)
3. Fast translation of biomarker research to implementation needed!
Omics: looking at everything
Role of omics in personalized healthcare
- Leads to
- Personalized diagnosis
- Personalized therapy
- Patient-doctor interaction
Power of omics in molecular analysis
Genomics: 3.000.000.000 DNA basis in 1 assay
Proteomics, glycomics, metabolomics: 10.000-50.000 proteins and metabolites in 1 assay
- Higher diagnostic yield
- Contextualisation of change (giving the bigger picture)
Integration of clinical omics data will drive personalized healthcare
1. Personalised diagnosis: by – omics
2. Elucidating new disease mechanisms: by deep learning, artificial intelligence, system biology
3. And monitoring new personalized (combination) therapies
Translational medicine: laboratory to society
- Using digital biomarkers
Laboratory: up to 1.000.00 signals per analysis
Society: point-of-care analysis of few biomarkers
,Lot of data: but not all date is useful data!
- Quality, not quantity
Translational innovation gaps
1. Research to research
2. Research to diagnostics
3. Research to society
So a lot of data: but half of the published data
cannot be reproduced
- Due to biological reagent and reference
materials
- Study design
- Data analysis and reporting
- Laboratory protocols
Example: biomarkers to support drug development in melanoma
- Need for blood-based biomarkers that indicate downstream effects of drug
o Inhibition of ERK pathway (pharmacodynamic)
o Tumor inhibition (efficacy)
After extensive transcriptomics profiling: IL-8 was a promising candidate biomarker
But, they also did a validation study to confirm IL-8 in melanoma to
1. Confirm elevated IL-8 in melanoma
2. Develop IL-8 assays for clinical use
- But IL-8 protein levels did not increase (significant) in plasma and serum (even though
literature confirmed this should be the case)
This was not published, because only positive outcomes are shared
- If we want to innovate clinical molecular biomarkers, we need to increase quality, not
quantity of our research
So in personalized healthcare
- Always focus on the end user: patient/ citizen
3 key aspects of personalized health(care)
1. What to measure
2. How much can it change
3. What should be the follow up for me
So, translation is key
Personal data → knowledge → understanding → decision → action
- Need for personalized data-driven GPS for health
o Monitor on background
o Alert when at risk
o Advice what to do
o Doctor as coach
And know, all this data can give a ‘funhouse mirror effect’: there is no single one reflection of health
, Tutorial: Pharmacology and drug disposition
Pharmacology: the science that is concerned with the use, effects and modes of action of chemicals
on the function of living systems
- Multidisciplinary field: molecule, cell, organ, organism, family and population
Pharmacotherapy:
- Patient
o What does the patient with the drug
o What does the drug with the patient
1. Pharmacokinetics: how does the drug travel through the body
2. Pharmacodynamics: if the drug reaches the target, how does it act?
You have both rational pharmacotherapy and evidence-based pharmacotherapy
1. Rational: mechanism-based pharmacotherapy
2. Evidence-based: does not matter how it works, as long as it works
Pharmacological phases in
pharmacotherapy
1. Exposition phase
2. Toxicokinetic phase
3. Toxicodynamic phase
Classification of pharmacological effects:
Agonist: activation of e.g. receptor → intracellular signal transduction
Antagonist: blocking of receptor → dysfunctional or no function of receptor
Classical drug-receptor interactions
1. Ligand-gated ion channels: milliseconds
2. G-protein-coupled receptors: seconds
3. Kinase-linked receptors: hours
4. Nuclear receptors: hours
- Thus, main difference = time-scale
Drug binding sites and interaction types
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper juliateders. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €6,89. Je zit daarna nergens aan vast.
Is Stuvia te vertrouwen?
4,6 sterren op Google & Trustpilot (+1000 reviews)
Afgelopen 30 dagen zijn er 53068 samenvattingen verkocht
Opgericht in 2010, al 14 jaar dé plek om samenvattingen te kopen